AprilBio Co.,Ltd. Q3 operating loss of KRW 3.4 billion on KRW 0.6 billion revenue (standalone)
AAI summary · Not investment advice
April Bio sold KRW 0.6 billion in Q3 but lost KRW 3.4 billion from its main business, and its net loss was KRW 4.6 billion versus KRW 5.0 billion a year earlier.}
Operating profit · 3 months
KRW -3.4 billion
Key facts
- Revenue (3 months)
- KRW 595.6 million
- Net income (3 months)
- KRW -4.6 billion
- Period
- Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
- Revenue (year to date)
- KRW 1.3 billion
- Operating profit (year to date)
- KRW -8.5 billion
- Net income (year to date)
- KRW -6.4 billion
- Net income (prior-year 3 months)
- KRW -5.0 billion
Commentary
AI commentary · Not investment advice
What happened
April Bio reported its 3rd-quarter results on a standalone basis. Sales for the 3 months were KRW 595.6 million. Cumulative sales this year were KRW 1.32 billion.
In the company's terms
Operating profit (profit from the core business) for the 3 months was a loss of KRW 3.35 billion. For the year so far, it was a loss of KRW 8.46 billion. The company spent more on its core business than it earned.
What changes for shareholders
Net income (the final profit after all costs and taxes) for the 3 months was a loss of KRW 4.60 billion. For the year so far, it was a loss of KRW 6.38 billion. In the same 3 months a year earlier, net income was a loss of KRW 4.96 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist